Abstract: A non-viral vector, comprising, from 5? to 3?, flanked by two transposon terminal inverted repeats, an inducible promoter, a first coding region comprising a specific combination of genes whose expression is localized to a tumor microenviorment and their function being mediators of CAR persistence and anti-tumor mechanisms to stimulate or enhance a patient anti-tumor response; a second promoter and coding region for expressing one or more artificial immunosurveillance chimeric antigen receptors (AI-CAR), and a truncated CD20 or truncated EGFR safety target. A polycistronic mRNA comprised of a specific combination of transiently expressed anti-tumor mechanisms designed to stimulate a patient anti-tumor response the same as an AI-CAR vector.

Abstract: The application provides non-viral vector, comprising an artificial immunosurveillance chimeric antigen receptor (AI-CAR) expression cassette flanked by two transposons or viral terminal repeats (IR), wherein the AI-CAR expression cassette comprises an inducible gene expression unit and a CAR expression unit.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: Methods are provided for inhibiting cell death or inflammation in a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation. The methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. Methods are also provided for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: The invention provides methods for inhibiting cell death or inflammation in a mammal brought about by diseases or conditions such as heart failure, wherein the method comprises administering to a mammal in need thereof a Bcl protein in an amount sufficient to inhibit cell death and inflammation in the mammal.

Abstract: Methods and compositions for the treatment or prevention of diseases or disorders including media conditioned by mesenchymal stem cells and BCL2A1 are provided. Methods for the production of therapeutic or preventative compositions contacted with BCL2A1 are also provided.

Abstract: Methods and compositions are provided for treating inflammatory-related diseases and related disorders in a mammalian subject. The method provides administering to the mammalian subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate the inflammatory-related disease or disorder or prevent its occurrence or recurrence. Methods are also provided for reducing or eliminating ligand-induced adhesion in a mammalian subject. The method provides administering to the subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate ligand-induced adhesion.

Abstract: The present invention provides an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor. The HMG-CoA reductase inhibitor can be, for example, a statin such as lovastatin, pravastatin, simvastatin, cerivastatin, fluvastatin, atorvastatin or mevastatin. The invention also provides a method of treating a pulmonary disease with an aerosol formulation of a HMG-CoA reductase inhibitor.

Abstract: A drive mechanism which permits both rotational and vertical translation of a fluid dispense arm within a wafer processing system. A motor drives a brake/clutch coupling which, through selective actuation and the utilization of two drive gears, causes selective rotation and/or translation of an output shaft attached to the fluid dispense arm. Selective rotation and/or translation of the output shaft and the fluid dispense arm permits the use of the apparatus without modification of the spin deflector and associated baffling in the wafer processing area.